Tackling Fuel Poverty in London

The challenge of economic and health inequalities caused by fuel poverty are rooted in the rise in fuel costs which have strong implications affecting the cost of living. Fuel costs and rising inflation due to economic and political reasons threaten individuals and families who are already struggling financially, putting them in/at risk of fuel poverty. The UK is one of the first countries to define the challenge of households living in fuel poverty prompting necessary actions, policies and interventions. This study presents the results of an empirical investigation following direct enquires to the Greater London Authority (GLA) and all of London boroughs via Freedom of Information (FOI) requests on retrofit interventions, including an overview of financial incentives and planning assessments with an aim to increase the number of home energy upgrades since April 2021. London adopted its own action plan in 2018 to renew its focus and alleviate more than 350,000 households in fuel poverty (GLA, 2018). The assessment and indicator for fuel poverty has changed over time, from the Low Income High Cost (LIHC) to Low Income Low Energy Efficiency (LILEE) indicator in 2021. However, identifying households in fuel poverty remains challenging and some indicators are somewhat disconnected from what is happening on the ground. The findings suggest that there is a need to establish tools and methodologies that are connected to the national and local context. Fuel poverty is affecting people’s health and well-being, particularly those already facing socio-economic and health inequalities. After the COVID pandemic, a political awareness of fuel poverty is found in the Mayoral manifesto, however the Fuel Poverty Action Plan does not have binding targets and is not regularly updated. Current Fuel Poverty Partnership Tasks are focusing on awareness and communication or the urgent support to households already affected, but not in tackling the root causes of fuel poverty in upgrading fuel poor homes. The uptake on retrofits from 2021 is still low and far from reaching 100k homes and the net zero target in 2030 is approaching fast. The study concludes that while LILEE is decreasing other indicators are increasing with rising energy prices. The London Building Stock Model is not widely used by boroughs, and it only maps the Energy Performance Certificate (EPC) rating which is not sufficient to identify households in fuel poverty. Most schemes such as Energy Companies Obligation (ECO) do not specifically target fuel poverty but have a wider scope of retrofit towards net zero. The Mayor of London should explore a new indicator tool by crossing data from LBSM with socio-economic data to identify fuel poor households more accurately. The indicator could potentially include geographical location, building typology (age, etc), socio-economic / demographics, leading to action plan and retrofit strategies

Beetles "in red": are the endangered flat bark beetles Cucujus cinnaberinus and C. haematodes chemically protected? (Coleoptera: Cucujidae)

Two native species of the genus Cucujus show a wide geographic distribution in Europe, Cucujus cinnaberinus (Scopoli, 1763) and C. haematodes Erichson, 1845. Although data on the distribution and ecology of these rare and endangered species are increasing, there are few reports on their biology and behaviour, and some aspects of their feeding ecology remain problematic. Our aim was to study, for the first time, the cuticular chemical profiles of these two beetles to (i) investigate the presence of chemicals potentially involved in defence by pathogens and (ii) lay the foundation for understanding the role of their bright red colour. The analysis of the cuticular profile was performed in-vivo by solid phase microextraction coupled with gas chromatography-mass spectrometry. In the cuticular profiles of the two species we identified 24 compounds belonging to different classes of molecules, i.e. hydrocarbons, aldehydes, esters, n-alkyl morpholines, and a high number of organic acids. Qualitative differences in terms of both signal intensity and detected compounds were found between the two species. As reported in other insects, the remarkable array of avoidance substances suggests a strict relationship with the bright red colour of the adults, which probably acts as an aposematic or warning signal. European Cucujus species are probably well protected against enemies because some identified chemicals, particularly fatty acids, are related to an anti-predatory strategy to fight off predators that use their sense of smell to locate their prey. Other substances found on the cuticular layer of these beetles are probably involved in an antimicrobial and antifungal function, as demonstrated in other insects living in habitats that host many pathogens

Drug design and synthesis of first in class PDZ1 targeting NHERF1 inhibitors as anticancer agents

Targeted approaches aiming at modulating NHERF1 activity, rather than its overall expression, would be preferred to preserve the normal functions of this versatile protein. We focused our attention on the NHERF1/PDZ1 domain that governs its membrane recruitment/displacement through a transient phosphorylation switch. We herein report the design and synthesis of novel NHERF1 PDZ1 domain inhibitors. These compounds have potential therapeutic value when used in combination with antagonists of β-catenin to augment apoptotic death of colorectal cancer cells refractory to currently available Wnt/β-catenin-targeted agents

PO-0632: Dose-volume related dysphagia in head and neck cancer Intensity Modulated Radiation Treatment

n/

Dose-volumerelated dysphagia after constrictor muscles definition in head and neck cancer intensitymodulated radiation treatment

OBJECTIVE: Dysphagia remains a side effect influencing the quality of life of patients with head and neck cancer (HNC) after radiotherapy. We evaluated the relationship between planned dose involvement and acute and late dysphagia in patients with HNC treated with intensity-modulated radiation therapy (IMRT), after a recontouring of constrictor muscles (PCs) and the cricopharyngeal muscle (CM). METHODS: Between December 2011 and December 2013, 56 patients with histologically proven HNC were treated with IMRT or volumetric-modulated arc therapy. The PCs and CM were recontoured. Correlations between acute and late toxicity and dosimetric parameters were evaluated. End points were analysed using univariate logistic regression. RESULTS: An increasing risk to develop acute dysphagia was observed when constraints to the middle PCs were not respected [mean dose (D(mean)) ≥50 Gy, maximum dose (D(max)) >60 Gy, V50 >70% with a p = 0.05]. The superior PC was not correlated with acute toxicity but only with late dysphagia. The inferior PC was not correlated with dysphagia; for the CM only, D(max) >60 Gy was correlated with acute dysphagia ≥ grade 2. CONCLUSION: According to our analysis, the superior PC has a major role, being correlated with dysphagia at 3 and 6 months after treatments; the middle PC maintains this correlation only at 3 months from the beginning of radiotherapy, but it does not have influence on late dysphagia. The inferior PC and CM have a minimum impact on swallowing symptoms. ADVANCES IN KNOWLEDGE: We used recent guidelines to define dose constraints of the PCs and CM. Two results emerge in the present analysis: the superior PC influences late dysphagia, while the middle PC influences acute dysphagia

Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1

Aims. The aims of this study were to evaluate the antitumor and antiangiogenic activity of metronomic ceramide analogs and to investigate their relevant molecular mechanisms. Methods. Human endothelial cells (HMVEC-d, HUVEC) and pancreatic cancer cells (Capan-1, MIAPaCa-2) were treated with the ceramide analogs (C2, AL6, C6 and C8), at low concentrations for 144h to evaluate any antiproliferative and pro-apoptotic effects, inhibition of migration, and to measure the expression of caveolin-1 (CAV-1) and thrombospondin-1 (TSP-1) mRNAs by real time RT-PCR. Assessment of ERK1/2 and Akt phosphorylation, and of CAV-1 and cyclin-D1 protein expression was performed by ELISA. Maximum tolerated dose (MTD) gemcitabine was compared against metronomic doses of the ceramide analogs by evaluating the inhibition of MIAPaCA-2 subcutaneous tumor growth in nude mice. Results. Metronomic ceramide analogs preferentially inhibited cell proliferation and enhanced apoptosis in endothelial cells. Low concentrations of AL6 and C2 caused a significant inhibition of HUVEC cell migration. ERK1/2 and Akt phosphorylation were significantly decreased after metronomic ceramide analog treatment. Such treatment caused the over-expression of CAV-1 and TSP-1 mRNA and protein in endothelial cells, whereas cyclin-D1 protein levels were reduced significantly. The antiangiogenic and antitumor impact in vivo of metronomic C2 and AL6 regimens was similar to that caused by MTD gemcitabine. C6 and C8 did not show any significant in vivo antitumor effects. Conclusions. Metronomic C2 and AL6 analogs have antitumor and antiangiogenic activity, determining the upregulation of CAV-1 and TSP-1 and the suppression of cyclin-D1